Inhibikase Therapeutics, Inc. (IKT) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.95
↓-13% vs avg
5yr avg: 1.09
30Y Low0.6·High7.1
ROE
↑
-36.0%
↓+45% vs avg
5yr avg: -65.8%
30Y Low-119%·High-36%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IKT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Inhibikase Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $119M | $202M | $225M | $7M | $13M | $27M | $69M | — | — | — | — |
| Enterprise Value | $-20645276 | $62M | $169M | $-1770144 | $6M | $-13733704 | $56M | — | — | — | — |
| P/E Ratio → | -3.41 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 26.00 | 102.12 | 8.63 | 99.29 | — | — | — | — |
| P/B Ratio | 0.95 | 1.17 | 2.38 | 0.62 | 0.60 | 0.70 | 7.09 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
IKT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | -6.80 | 46.73 | -4.43 | 79.77 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
IKT Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -36.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | -5127.8% | 94.6% | -266.4% | -28.0% | -127.4% | 9.7% | 14.8% | 12.5% |
| Operating Margin | — | — | — | -7712.0% | -14686.2% | -476.2% | -403.5% | -507.5% | -52.5% | -19.7% | -63.4% |
| Net Profit Margin | — | — | — | -7304.8% | -14625.9% | -476.9% | -407.7% | -509.7% | -53.3% | -21.2% | -65.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -36.0% | -36.0% | -52.0% | -118.9% | -60.7% | -61.4% | -107.6% | — | — | — | — |
| ROA | -34.5% | -34.5% | -48.7% | -96.5% | -53.6% | -51.7% | -38.4% | -396.8% | -137.5% | -194.6% | -385.9% |
| ROIC | -108.0% | -108.0% | -104.8% | -181.2% | -224.5% | — | — | — | — | — | — |
| ROCE | -38.8% | -38.8% | -54.0% | -124.4% | -60.8% | -60.9% | -96.4% | — | — | — | — |
IKT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $139M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.00 | 0.06 | 0.02 | 0.01 | 0.03 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.81 | -0.59 | -0.78 | -0.33 | -1.05 | -1.39 | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | -0.20 | — | — |
| Interest Coverage | — | — | — | — | -242.49 | -741.16 | -95.86 | -229.44 | -69.96 | — | — |
Net cash position: cash ($139M) exceeds total debt ($0)
IKT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Inhibikase Therapeutics, Inc.'s current ratio of 21.70x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.13x to 21.70x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 21.70 | 21.70 | 26.37 | 4.13 | 6.59 | 10.47 | 3.13 | 0.01 | 0.35 | 0.11 | 0.05 |
| Quick Ratio | 21.70 | 21.70 | 26.37 | 4.13 | 6.59 | 10.47 | 3.13 | 0.01 | 0.35 | 0.11 | 0.05 |
| Cash Ratio | 21.54 | 21.54 | 26.13 | 3.85 | 6.24 | 10.05 | 2.96 | 0.00 | 0.10 | 0.01 | 0.01 |
| Asset Turnover | — | — | — | 0.02 | 0.00 | 0.07 | 0.05 | 29.35 | 1.42 | 7.23 | 5.94 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | 999999.00 |
| Days Sales Outstanding | — | — | — | — | 117.92 | 12.97 | — | — | 42.72 | 32.02 | 25.23 |
IKT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Inhibikase Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $98M | $69M | $5M | $4M | $3M | $2M | $2M | $1M | $2M | $1M |
Peer Comparison
Compare IKT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IKTYou | $119M | -3.4 | — | — | — | — | -36.0% | -108.0% | — |
 PRTA | $432M | -1.8 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ACAD | $4B | 9.3 | 25.5 | 34.8 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 SAVA | $64M | -2.5 | — | — | — | — | -17.2% | -634.1% | — |
 NRXP | $68M | -2.9 | — | — | 58.8% | -1324.4% | — | — | — |
 INVA | $2B | 6.8 | 6.7 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 AVXL | $232M | -4.6 | — | — | — | — | -43.1% | — | — |
 ACIU | $230M | -2.6 | — | — | 100.0% | -1927.3% | -89.6% | -99.2% | — |
 ATHA | $17M | -0.2 | — | — | — | — | -290.8% | — | — |
 ANVS | $36M | -1.3 | — | — | — | — | -220.6% | — | — |
 CRL | $9B | -64.6 | 13.1 | 17.5 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
What if you invested $1,000 in IKT 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in IKT be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs IKT Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationIKT vs PRTA — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Prothena Corporation plc.
Compare NowIKT — Frequently Asked Questions
Quick answers to the most common questions about buying IKT stock.
What is Inhibikase Therapeutics, Inc.'s P/E ratio?
Inhibikase Therapeutics, Inc.'s current P/E ratio is -3.4x. This places it at the 50th percentile of its historical range.
What is Inhibikase Therapeutics, Inc.'s ROE?
Inhibikase Therapeutics, Inc.'s return on equity (ROE) is -36.0%. The historical average is -72.8%.
Is IKT stock overvalued?
Based on historical data, Inhibikase Therapeutics, Inc. is trading at a P/E of -3.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.